The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You not know about code 64?
For now....
Why i wonder lol - been there seen that
Let’s see if PYC Twitter team or whatever it’s called jumps all over that tweet….
“Scratches chin”
Very possible…I mean why would they just add this now?
2024 Outlook
The FDA recommendation in early 2023 to use AUC is an important and significant shift in vancomycin dosing and monitoring augmenting the mission to advance better patient outcomes. Research reports continue to include precision medicine, and dosing specifically, as a key trend in 2024 and beyond.
Among the operational plans for 2024, DoseMe will continue to build new drug models to broaden the MIPD platform, diversify the channels and add new partners that will enable the company to offer a wide range of AI-powered systems for real-time patient care.
More interesting DosemeRX have added Docetaxel to there under development part of there oncology section on the website….This is from the PYC integration and this has only just been added to the site…..
https://doseme-rx.com/why-dosemerx/drug-packages
New Tweet & Business update from Dosemerx
https://doseme-rx.com/news-media/articles/doseme-2023-highlights-and-2024-trends
New uncle
This ……emoji pointing down lol nailed it
Have you submitted the questions?
Agreed- think people will be caught offside here.
Bends my head Peter was announced as coo 20% up announced a ceo 10% down
Saying that probs just the people jumped in on that slight rise Friday… bailing
When Peter was appointed COO the shares went up 20% now CEO……Maths….?
Physiomics PLC on Monday named Peter Sargent as its new chief operating officer.
Shares in Physiomics were up 21% at 1.90 pence each in London on Monday morning.
The mathematical modelling company that supports oncology drug development said the hire is part of its strategy to revert to a "more traditional" board structure, where the roles of executive chair and chief executive officer are separated.
Under the role, Sargent will help to formulate the firm's business strategy and drive its execution, focusing on key priorities such as expanding and diversifying its client base, expanding consulting business into pharmaceutical biostatistics, and exploring opportunities for its personalised oncology software offering.
Sargent was previously in a senior management role at Nasdaq-listed Syneos Health Inc, a global consultancy business, and also served as head of Business Development at the UK's National Institute for Health & Care Research.
Back in January, former COO Christophe Chassagnole's job title changed to chief scientific officer after the company decided that the new title aligned more closely with his role and responsibilities.
Chair & Chief Executive Officer Jim Millen said: "I am delighted that Physiomics has been able to attract a candidate of the calibre of Peter Sargent, who joins us with significant experience of building service businesses in the biopharmaceutical sector.
"Peter will work closely with myself and my senior management team to set and drive forwards the company's key business priorities, and I look forward to him making a significant positive impact."
Valid questions…
I do think Peter has a lot to bring to the table mind…
Prior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his earlier roles, Dr Sargent has also been Head of Business Development for the UK’s National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.
Syneos
After months of sale speculation, Syneos Health has officially been snapped up by three private investment firm affiliates for the eye-watering sum of $7.1 billion. October 23
Strong News Flow Due…..
A raft of contracts £££ (see novembers presentation)
Sheffield Uni colab
Blackpool NHS Collab
NIHR contract Update
Cancer Research UK Update
DosemeRX Update
Can’t not disagree with the 200dma
But…. Bearish meaning Monday ? Or hours?
Frankly the facts are that the MM will take large volumes of shares off your hands without being NT states they want your shares….thats the market…
This could easily be sitting at 5-6 p in no time at all with a minimal MC still.
It’s there to be seen but hey….
A few buys can send this west.
It’s happened before late on on a Friday….
Either way it is what it is….
All in the right direction….
We going again?????
Think it was 3 at type of writing - apologies if Incorrect
Either way….being held….
If you have watched PYC over a lengthy period as I have and others it’s clear as day….
Any questions about it people need to watch the presentation….and by the number of views it’s had I’d say people haven’t…..
Traders will trader for there few £100 quid….thats the game and they can do.
But I’d rather have a multi bagger potential that run around chasing rainbows….
Valid point.